Georgiamune is focused on reprogramming immune responses to restore immune homeostasis, particularly in the context of cancer and autoimmune diseases. The company employs innovative strategies to regulate immune signaling pathways, aiming to either activate or down-modulate the immune system. Their approach includes the development of targeted, novel drugs designed to rebalance immune system components, which is crucial for addressing the challenges posed by disrupted immune homeostasis. Georgiamune's pipeline features a range of first-in-class immunomodulators, including dual-functioning antibodies and small molecules, that are capable of enhancing or inhibiting various signaling pathways to combat these diseases.

Among their notable products are GIM-122, a dual-functioning antibody that aims to overcome cancer-mediated immune suppression while stimulating activated T cells, and GIM-531, a small molecule that selectively inhibits regulatory T cells (Tregs) to reprogram the tumor microenvironment. Additionally, GIM-407 is designed to enhance the quantity and function of Tregs, targeting autoimmune conditions by restoring immune tolerance. Georgiamune's commitment to advancing immunotherapeutics is supported by a robust target discovery platform and a team of experienced professionals dedicated to addressing significant unmet medical needs in oncology and autoimmune disease management.

United States

Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.

Georgiamune

Company Details